Search clinical trials for: rituximab

Total 2308 results

Asociacion Doctor Peset Para el Estudio de la Hematología
Cephalon; Pivotal S.L.

Unknown

Ciclophosphamide, Vincristine, Myocet and Prednisone, With Rituximab in 1st-Line Treatment for Patients With No-Hodgkin B Lymphoma and Cardiovascular (CV) Risk

No Hodgkin B Lymphoma

Spain
French Innovative Leukemia Organisation
Hoffmann-La Roche

Completed

Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years

Mantle Cell Lymphoma

France
University of Turku
Finnish Institute for Health and Welfare

Unknown

Amoxicillin Clavulanate in Treatment of Acute Otitis Media

Acute Otitis Media

Finland
Eastern Cooperative Oncology Group
National Cancer Institute (NCI); Cancer and Leukemia Group B

Completed

Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell Lymphoma

Lymphoma
Stanford University
Genentech and Biogen IDEC

Completed

Rituximab for Pediatric Renal Transplant Rejection

Kidney Transplantation

United States
Maisonneuve-Rosemont Hospital
Bayer

Unknown

Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma

Non-Hodgkins Lymphoma

Canada
University Hospital Tuebingen
Hoffmann-La Roche

Completed

Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Primary Gastric Diffuse-Large B-Cell Lymphoma

Germany
Assistance Publique - Hôpitaux de Paris

Terminated

Amoxicillin Susceptibility of Oral Streptococci After a 3-Day or a 7-Day Amoxicillin Therapy (ODAMOX)

Odontogenic Infection

France
University of Alabama at Birmingham

Completed

Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura

Purpura, Thrombocytopenic, Idiopathic

United States
ZymoGenetics

Completed

Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin

United States
University of Cologne

Completed

Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)

Lymphocyte Predominant Hodgkin´s Lymphoma (LPHD)

Germany
University of Bern
Hoffmann-La Roche; Swiss National Science Foundation

Completed

Immunopharmacological Effects of Rituximab in Atopic Dermatitis

Dermatitis, Atopic

Switzerland
Hunter and New England Health
Melbourne Health; Royal Prince Alfred Hospital, Sydney, Australia; Princess Alexandra... and other collaborators

Unknown

Trial of Rituximab Given Pre-Transplant to Sensitised Live Donor Kidney Recipients (RAPTURE)

Kidney Transplantation

Australia
Chinese University of Hong Kong

Completed

An Analysis of Peripheral Blood T Cell Subsets on Rheumatoid Arthritis

Rheumatoid Arthritis

China
Tehran University of Medical Sciences
Hoffmann-La Roche

Completed

Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease

Behcet's Syndrome

Iran, Islamic Republic of
US Oncology Research
Fred Hutchinson Cancer Center; Chiron Corporation

Terminated

Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

United States
Cedars-Sinai Medical Center
Genentech, Inc.; Biogen

Completed

Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation

Kidney Transplant

United States
Genitope Corporation

Terminated

Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma

Non-Hodgkin's Lymphoma

United States
National Institute of Allergy and Infectious Diseases...

Completed

An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies

Wegener's Granulomatosis

United States
National Cancer Institute (NCI)

Completed

A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab

Stomach Neoplasms | Breast Neoplasms | Lung Neoplasms | Pancreatic Neoplasms | Colonic Neoplasms

United States
Millennium Pharmaceuticals, Inc.

Completed

VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma

Follicular Lymphoma | B-Cell Lymphoma | Marginal Lymphoma

United States
Genta Incorporated

Withdrawn

This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL)

Lymphocytic Leukemia
University of Virginia
National Cancer Institute (NCI)

Terminated

Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Lymphoma

United States
University of Michigan Rogel Cancer Center

Terminated

Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin's

United States
Karolinska University Hospital

Completed

Safety and Efficacy Study of Rituximab in Renal Transplantation

Renal Transplantation

Sweden
Keio University

Terminated

Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin

Japan
Assistance Publique - Hôpitaux de Paris

Completed

RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides

Wegener's Granulomatosis | Microscopic Polyangiitis | Churg-Strauss Syndrome

France
Geriatric Oncology Consortium
Tibotec Pharmaceutical Limited

Terminated

Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients

Non-Hodgkin's Lymphoma

United States
Gruppo Italiano Multiregionale per lo studio dei...

Completed

Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-Cell Lymphoma | POOR PROGNOSIS

Italy
InterMune

Terminated

Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients

Non-Hodgkin's Lymphoma

United States
Lymphoma Study Association

Completed

Study for Newly Diagnosed Follicular Lymphoma Patients With a Large Tumor Burden

Lymphoma

France, Belgium
Tel-Aviv Sourasky Medical Center

Terminated

The Effect of Rituximab on the Humoral Response to Influenza Vaccine

Rheumatoid Arthritis
Azienda Ospedaliera San Giovanni Battista
Hoffmann-La Roche; University of Turin, Italy; Gruppo Italiano Trapianto di Midollo... and other collaborators

Unknown

Comparison of High-Dose Chemotherapy + Rituximab and CHOP + Rituximab in High-Risk Follicular Lymphoma

Follicular Lymphoma

Italy
Charite University, Berlin, Germany
Hoffmann-La Roche

Unknown

Open Label Clinical Trial With Rituximab (MabThera ®) in Ankylosing Spondylitis

Ankylosing Spondylitis

Germany
Instituto Nacional de Cancerologia de Mexico

Unknown

Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.

Non-Hodgkin Lymphoma

Mexico
French National Agency for Research on AIDS and...
Hoffmann-La Roche

Terminated

Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy

HIV Infections | Giant Lymph Node Hyperplasia
Gruppo Italiano Studio Linfomi

Completed

Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab

Follicular Lymphoma

Italy
Medical University of Vienna

Unknown

Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma

Lymphoma, Mantle-Cell

Austria
Odense University Hospital

Completed

Rituximab in the Treatment of Graves' Disease

Thyroid Associated Ophthalmopathy | Graves´ Disease

Denmark
University of Magdeburg

Unknown

Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL

Lymphoma, High-Grade

Germany
University of Magdeburg

Unknown

Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma

Non-Hodgkin's Lymphoma

Germany
The Alvin and Lois Lapidus Cancer Institute
Ortho Biotech Products, L.P.

Unknown

A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.

Lymphoma, Non-Hodgkin | Diffuse Large B Cell Lymphoma

United States
Biogen

Terminated

Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

United States
Gustave Roussy, Cancer Campus, Grand Paris
Hoffmann-La Roche

Terminated

Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL

Burkitt Lymphoma

France
Gustave Roussy, Cancer Campus, Grand Paris

Unknown

LMBA02 Protocol for Patients With a Burkitt Lymphoma

Burkitt Lymphoma

France
Hamamatsu University

Unknown

Second Line Therapy for the Cure of Helicobacter Pylori (H. Pylori) Infection

Gastritis | Helicobacter Infections | Gastric Ulcer | Duodenal Ulcer

Japan
Cambridge University Hospitals NHS Foundation Trust
Roche Pharma AG

Completed

Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis

Systemic Lupus Erythematosus | ANCA Associated Vasculitis

United Kingdom
Chiron Corporation

Completed

Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments

Lymphoma, Non-Hodgkin

United States
Chiron Corporation

Terminated

Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin Lymphoma

United States
Chiron Corporation

Completed

Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.

Lymphoma, Non-Hodgkin

United States

Search clinical trials for: rituximab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations